ImmuCell Corporation (ICCC) - Net Assets
Based on the latest financial reports, ImmuCell Corporation (ICCC) has net assets worth $29.80 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($45.73 Million) and total liabilities ($15.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ICCC cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $29.80 Million |
| % of Total Assets | 65.17% |
| Annual Growth Rate | 6.16% |
| 5-Year Change | -2.65% |
| 10-Year Change | 159.27% |
| Growth Volatility | 25.29 |
ImmuCell Corporation - Net Assets Trend (1989–2024)
This chart illustrates how ImmuCell Corporation's net assets have evolved over time, based on quarterly financial data. Also explore ICCC asset base for the complete picture of this company's asset base.
Annual Net Assets for ImmuCell Corporation (1989–2024)
The table below shows the annual net assets of ImmuCell Corporation from 1989 to 2024. For live valuation and market cap data, see ImmuCell Corporation (ICCC) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $27.52 Million | +10.10% |
| 2023-12-31 | $24.99 Million | -17.73% |
| 2022-12-31 | $30.38 Million | -6.74% |
| 2021-12-31 | $32.58 Million | +15.25% |
| 2020-12-31 | $28.27 Million | -2.50% |
| 2019-12-31 | $28.99 Million | +33.33% |
| 2018-12-31 | $21.74 Million | -7.84% |
| 2017-12-31 | $23.59 Million | +19.64% |
| 2016-12-31 | $19.72 Million | +85.82% |
| 2015-12-31 | $10.61 Million | +14.64% |
| 2014-12-31 | $9.26 Million | -1.46% |
| 2013-12-31 | $9.40 Million | +2.19% |
| 2012-12-31 | $9.19 Million | +1.93% |
| 2011-12-31 | $9.02 Million | -2.82% |
| 2010-12-31 | $9.28 Million | -3.53% |
| 2009-12-31 | $9.62 Million | -0.23% |
| 2008-12-31 | $9.64 Million | -4.11% |
| 2007-12-31 | $10.06 Million | +7.77% |
| 2006-12-31 | $9.33 Million | +9.05% |
| 2005-12-31 | $8.56 Million | +10.72% |
| 2004-12-31 | $7.73 Million | +4.86% |
| 2003-12-31 | $7.37 Million | +5.98% |
| 2002-12-31 | $6.95 Million | +15.03% |
| 2001-12-31 | $6.05 Million | +9.15% |
| 2000-12-31 | $5.54 Million | +96.74% |
| 1999-12-31 | $2.82 Million | +27.97% |
| 1998-12-31 | $2.20 Million | -4.35% |
| 1997-12-31 | $2.30 Million | +21.05% |
| 1996-12-31 | $1.90 Million | 0.00% |
| 1995-12-31 | $1.90 Million | 0.00% |
| 1994-12-31 | $1.90 Million | -17.39% |
| 1993-12-31 | $2.30 Million | +27.78% |
| 1992-12-31 | $1.80 Million | +20.00% |
| 1991-12-31 | $1.50 Million | -46.43% |
| 1990-12-31 | $2.80 Million | -17.65% |
| 1989-12-31 | $3.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ImmuCell Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1056372600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $904.24K | 3.29% |
| Other Comprehensive Income | $26.41 Million | 95.98% |
| Other Components | $14.37 Million | 52.21% |
| Total Equity | $27.52 Million | 100.00% |
ImmuCell Corporation Competitors by Market Cap
The table below lists competitors of ImmuCell Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PDS Biotechnology Corp
NASDAQ:PDSB
|
$54.76 Million |
|
Falcon Machine Tools Co Ltd
TWO:4513
|
$54.77 Million |
|
biote Corp
NASDAQ:BTMD
|
$54.78 Million |
|
Wisekey International Holding AG
NASDAQ:WKEY
|
$54.81 Million |
|
ZEN Graphene Solutions Ltd
NASDAQ:ZTEK
|
$54.73 Million |
|
Shinih Enterprise Co Ltd
TW:9944
|
$54.72 Million |
|
Tunas Alfin Tbk
JK:TALF
|
$54.72 Million |
|
Sonel S.A.
WAR:SON
|
$54.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ImmuCell Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 24,993,077 to 27,518,187, a change of 2,525,110 (10.1%).
- Net loss of 2,156,629 reduced equity.
- New share issuances of 4,648,022 increased equity.
- Other comprehensive income increased equity by 26,411,671.
- Other factors decreased equity by 26,377,954.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.16 Million | -7.84% |
| Share Issuances | $4.65 Million | +16.89% |
| Other Comprehensive Income | $26.41 Million | +95.98% |
| Other Changes | $-26.38 Million | -95.86% |
| Total Change | $- | 10.10% |
Book Value vs Market Value Analysis
This analysis compares ImmuCell Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.11x to 2.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-12-31 | $1.71 | $8.73 | x |
| 1990-12-31 | $1.31 | $8.73 | x |
| 1991-12-31 | $0.74 | $8.73 | x |
| 1992-12-31 | $0.99 | $8.73 | x |
| 1993-12-31 | $0.87 | $8.73 | x |
| 1994-12-31 | $0.72 | $8.73 | x |
| 1995-12-31 | $0.76 | $8.73 | x |
| 1996-12-31 | $0.70 | $8.73 | x |
| 1997-12-31 | $0.77 | $8.73 | x |
| 1998-12-31 | $0.91 | $8.73 | x |
| 1999-12-31 | $1.12 | $8.73 | x |
| 2000-12-31 | $1.96 | $8.73 | x |
| 2001-12-31 | $2.16 | $8.73 | x |
| 2002-12-31 | $2.51 | $8.73 | x |
| 2003-12-31 | $2.61 | $8.73 | x |
| 2004-12-31 | $2.61 | $8.73 | x |
| 2005-12-31 | $2.85 | $8.73 | x |
| 2006-12-31 | $3.06 | $8.73 | x |
| 2007-12-31 | $3.31 | $8.73 | x |
| 2008-12-31 | $3.33 | $8.73 | x |
| 2009-12-31 | $3.25 | $8.73 | x |
| 2010-12-31 | $3.12 | $8.73 | x |
| 2011-12-31 | $3.02 | $8.73 | x |
| 2012-12-31 | $2.96 | $8.73 | x |
| 2013-12-31 | $3.05 | $8.73 | x |
| 2014-12-31 | $3.06 | $8.73 | x |
| 2015-12-31 | $3.35 | $8.73 | x |
| 2016-12-31 | $4.55 | $8.73 | x |
| 2017-12-31 | $4.77 | $8.73 | x |
| 2018-12-31 | $3.96 | $8.73 | x |
| 2019-12-31 | $4.25 | $8.73 | x |
| 2020-12-31 | $3.92 | $8.73 | x |
| 2021-12-31 | $4.29 | $8.73 | x |
| 2022-12-31 | $3.92 | $8.73 | x |
| 2023-12-31 | $3.23 | $8.73 | x |
| 2024-12-31 | $3.37 | $8.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ImmuCell Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.14%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.64x
- Recent ROE (-7.84%) is below the historical average (-3.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | -29.41% | -35.71% | 0.70x | 1.18x | $-1.34 Million |
| 1990 | -21.43% | -20.00% | 0.88x | 1.21x | $-880.00K |
| 1991 | -93.33% | -63.64% | 1.00x | 1.47x | $-1.55 Million |
| 1992 | -11.11% | -6.45% | 1.35x | 1.28x | $-380.00K |
| 1994 | -5.26% | -2.27% | 1.42x | 1.63x | $-290.00K |
| 1996 | -5.26% | -2.27% | 1.42x | 1.63x | $-290.00K |
| 1997 | 13.04% | 6.52% | 1.44x | 1.39x | $70.00K |
| 1998 | -4.55% | -2.22% | 1.45x | 1.41x | $-320.00K |
| 1999 | 19.57% | 11.22% | 1.27x | 1.37x | $269.30K |
| 2000 | 40.12% | 39.43% | 0.87x | 1.16x | $1.67 Million |
| 2001 | 6.95% | 6.29% | 0.94x | 1.18x | $-184.60K |
| 2002 | 12.74% | 14.33% | 0.82x | 1.08x | $190.78K |
| 2003 | 5.58% | 12.25% | 0.41x | 1.11x | $-325.83K |
| 2004 | 1.86% | 3.88% | 0.39x | 1.23x | $-629.37K |
| 2005 | 8.27% | 14.20% | 0.50x | 1.16x | $-147.97K |
| 2006 | 6.93% | 13.48% | 0.42x | 1.22x | $-286.06K |
| 2007 | 6.58% | 10.91% | 0.58x | 1.04x | $-343.56K |
| 2008 | -4.86% | -10.11% | 0.46x | 1.05x | $-1.43 Million |
| 2009 | -2.25% | -4.80% | 0.45x | 1.04x | $-1.18 Million |
| 2010 | -4.14% | -8.77% | 0.41x | 1.16x | $-1.31 Million |
| 2011 | -4.54% | -8.01% | 0.47x | 1.22x | $-1.31 Million |
| 2012 | 0.97% | 1.66% | 0.49x | 1.20x | $-829.96K |
| 2013 | 1.25% | 1.95% | 0.55x | 1.17x | $-822.19K |
| 2014 | -1.81% | -2.20% | 0.69x | 1.19x | $-1.09 Million |
| 2015 | 11.43% | 11.86% | 0.70x | 1.38x | $151.86K |
| 2016 | 2.58% | 5.33% | 0.39x | 1.25x | $-1.46 Million |
| 2017 | -0.71% | -1.61% | 0.30x | 1.45x | $-2.53 Million |
| 2018 | -10.68% | -21.14% | 0.34x | 1.51x | $-4.50 Million |
| 2019 | -4.47% | -9.44% | 0.35x | 1.33x | $-4.20 Million |
| 2020 | -3.62% | -6.66% | 0.38x | 1.43x | $-3.85 Million |
| 2021 | -0.24% | -0.41% | 0.43x | 1.36x | $-3.34 Million |
| 2022 | -8.21% | -13.43% | 0.41x | 1.48x | $-5.53 Million |
| 2023 | -23.10% | -33.05% | 0.40x | 1.75x | $-8.27 Million |
| 2024 | -7.84% | -8.14% | 0.59x | 1.64x | $-4.91 Million |
Industry Comparison
This section compares ImmuCell Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ImmuCell Corporation (ICCC) | $29.80 Million | -29.41% | 0.53x | $54.73 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotaviru… Read more